Alzheimer's Disease: Where Do We Stand Now? is organized by ContinuingEducation.com - OnCourse Learning Corporation and will be held during Jan 16, 2013 - Mar 27, 2020.
The target audience for this medical event is multiple professions, including pharmacists, pharmacy techs, and physicians. This CME Conference has been approved for a maximum of 2.00 Contact Hours.
Course Description :
The treatment approach to managing patients with dementia caused by Alzheimer’s disease (AD) is only through symptom control. The pathophysiology is not entirely known, and there is no drug available to prevent or cure the disorder. All FDA-approved drugs work by modulating neurotransmitters, either acetylcholine or glutamate. The two basic classes of drugs used to manage symptoms of AD are acetylcholinesterase inhibitors (AcHEI) and partial N-methyl-D-aspartate (NMDA) receptor antagonists. In addition, medications to control mood and behavior are used. These drugs are used to relieve depression, agitation, and insomnia, and include antidepressants, neuroleptics, anxiolytics, and anticonvulsants. As more research is completed and data collected, possible links to genetics, nutrition, and chemical entities may provide insight into future modes of therapy.
Conference Objectives are :
The goal of this dementia caused by Alzheimer’s disease (AD) continuing education program is to provide pharmacists and physicians with knowledge about the clinical aspects of managing patients with AD. After studying the information presented here, you will be able to:
• Describe the approved drugs used to treat patients with AD
• List the available drug treatments for secondary features of AD
• Discuss supplements and nonpharmacologic interventions used in managing symptoms of AD
• Review emerging therapies and areas of research for AD
Additional details will be posted as soon as they are available.